+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 22Years - 90Years
All Genders
ID07059754

Study to Assess Effects of the ETX-4143 Cooling Device on Eye Surface and Inflammation in Adults with Chronic Ocular Surface Pain

Led by EyeCool Therapeutics, Inc. · Updated on 2026-05-26

5

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the effects of an investigational cold treatment device called ETX-4143 on the eyes surface anatomy and inflammatory response in people with chronic ocular surface pain COSP. This study aims to understand changes to corneal surface nerves and inflammatory mediators after treatment, while also evaluating the safety of this cooling device. The study involves detailed imaging and tear sample analysis to learn more about the condition and treatment impact. The ETX-4143 Device is a handheld cooling tool containing a frozen mixture that cools metallic probes touching the eyes conjunctival surface without direct contact with the frozen mixture. Before treatment, local anesthesia and a corneal shield are applied to protect the eye. Participants will receive a 4-minute cold treatment to the worse eye using this device. This single-center study will treat 5 adults with chronic ocular surface pain and follow them for 12 weeks. Participants will be screened for chronic ocular surface pain and will complete weekly eye pain questionnaires for 12 weeks. Clinic visits at 2, 6, and 12 weeks after treatment will include corneal surface imaging and tear sample collection. Both eyes will be assessed with confocal microscopy and tear osmolarity tests, using the untreated eye as a control. The main measurement is corneal nerve imaging analysis over the 12-week period, alongside safety monitoring by the medical team.

CONDITIONS

Brief Title

A Clinical Study to Determine What Effect the EyeCool Treatment Has on the Eye's Surface Anatomy and Inflammation Response After Being Treated for Having Chronic Ocular Surface Pain (COSP)

Who Can Participate

Age: 22Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Documented symptoms of chronic ocular surface pain for at least 3 months
  • A score of 5 or higher on the single question COP-Q Eye Pain Severity Module
  • Able to obtain sufficient quality corneal in-vivo confocal microscopy images
  • Aged between 22 and 90 years
Not Eligible

You will not qualify if you...

  • Less than 50% improvement in VAS Eye Pain score after topical 0.5% proparacaine hydrochloride at screening
  • Clinically significant corneal scarring that could limit confocal microscopy
  • Insufficient number of corneal nerves to permit Fun-IVCM imaging

Research Team

P

Patrick Casey, Optometrist

C

Cristos Ifantides A Prospective, Feasibility, Single-Center, Clinical Study to E

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here